Can a new nucleotide analogue boost cancer treatment?
NCT ID NCT05714553
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The goal is to see if these combinations are safe and can shrink tumors in patients who have already tried other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental nucleotide analogue called NUC-3373, given with leucovorin and either pembrolizumab or docetaxel
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits and risks are not yet clear. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guy's and St Thomas NHS Foundation Trust
London, SE1 9RT, United Kingdom
-
Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust
Birmingham, B15 2TH, United Kingdom
-
The Beatson West of Scotland Cancer Centre
Glasgow, G12 0TN, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a blast of radiation make immunotherapy work better against kidney cancer?